Better Health for All

Sartorius's core business, providing solutions for biopharmaceutical manufacturing, drug discovery, and advanced cell models, delivers exceptional health benefits by accelerating the development of vaccines, antibodies, and cell therapies for serious conditions like cancer, infectious, neurological, and autoimmune diseases.

The company's products are ISO9001-certified for quality management. No products with significant negative health impacts are mentioned. In 2024, Sartorius allocated 2% of its sales to capitalized R&D. The company made donations totaling 85,000 euros in 2019 and 2020 to action medeor for pharmaceutical training and healthcare support in Tanzania and the Democratic Republic of Congo, and 46,000 euros to SOS Children's Village in Bangalore. In 2019, Sartorius Stedim Biotech, a subsidiary, donated $1.5 million to Penn State for a cell culture facility to support biotechnology research and training, including COVID-19 antibody development. Action medeor's project in Tanzania supports 8,954 students in 22 pharmaceutical schools and aims to add 150 more students at a new institute, targeting young people in rural areas. The company's support for action medeor also included medical equipment and nutritional supplements in the Democratic Republic of Congo.

Fair Money & Economic Opportunity

Sartorius AG is a partner of the biopharmaceutical industry and laboratories, providing equipment, instruments, consumables, and services. The company's core business does not involve offering lending, deposit services, insurance, or any other financial products to consumers or businesses.

Therefore, all KPIs related to 'Fair Money & Economic Opportunity' are not applicable, as the company does not operate in the financial services sector. The provided articles detail sustainability efforts, diversity and inclusion initiatives, and community engagement, including philanthropic contributions, but none of this evidence pertains to financial products, services, or economic opportunity for underserved populations in a financial context.

Fair Pay & Worker Respect

As of December 31, 2024, 99.92% of Sartorius employees were paid at or above a locally defined adequate wage.

The ratio of the highest paid individual's annual total remuneration to the median employee's total remuneration was 32 in 2024. In 2024, 52% of all employees were covered by collective bargaining agreements. The recordable occupational injury rate for employees was 3.3 per 1,000,000 hours worked in 2024, with no fatalities. The gender pay gap among employees in 2024 was 11%, meaning women earned on average 89% of what men earned overall. The Employee Net Promoter Score (eNPS) was -2.98 points in 2024. The employee fluctuation rate was 11.4% in 2024. In 2024, 25 complaints of discrimination, including harassment, were submitted, with one being substantiated or partially substantiated. The share of temporary employees was 7.8% in 2023.

Honest & Fair Business

Sartorius AG reported zero ethics-related fines for severe human rights incidents and employee incidents, and stated that fines for anti-corruption and anti-bribery violations were immaterial in the past three years.

The company has not made any financial restatements in the reporting year, which is its first Sustainability Statement in accordance with ESRS. Sartorius has a comprehensive 'Speak-Up Policy' and 'Rules of Procedure for Whistleblowers', offering multiple anonymous reporting channels available 24/7 in many languages, including a portal, hotline, and email. The policy applies to all employees and third parties, commits to non-retaliation for good faith reporting, and ensures confidentiality. Acknowledgement of receipt for complaints is provided within seven days, and accused persons are generally informed within one month. However, only 50% of the Supervisory Board members are assessed as independent. For transparency, Sartorius has an EcoVadis score of 65/100. The company has a robust Anti-Corruption Code, updated in January 2026, which prohibits facilitation payments and kickbacks, sets a general gift limit of €100 per year, and requires employees to complete role-specific, mandatory online training annually. Third-party due diligence is performed on a risk-oriented basis, and Sartorius sites have been externally audited according to PSCI standards since 2022. Some environmental management systems are externally certified to ISO 14001.

Kind to Animals

Sartorius is actively engaged in developing and promoting alternative testing methods. The company's Lab Products & Services Division works with partners to replace animal-based research models with organoids, and it acquired MatTek Corp. in July 2025, a company specializing in human cell-based microtissues that reduce the need for animal testing.

The company also invests in a minority shareholding in TheWell Bioscience, which offers animal-free hydrogels and bioinks. Sartorius's policy prohibits discretionary animal testing, with exceptions requiring high-level sign-off. The company's R&D expenses were €196.8 million in 2024, but the specific percentage allocated to animal-free technologies is not stated. Sartorius is a founder of the Sartorius-AI-Lab (SAIL) research laboratory and collaborates with MatTek and TheWell Bioscience on advanced cell models. The company hosted a round table at the Falling Walls Science Summit 2024 to discuss overcoming animal testing with advanced cell models, including regulatory guidance, and advocates for specific welfare standards.

Planet-Friendly Business

In 2024, the company's total Scope 1, 2, and 3 greenhouse gas emissions (market-based) were 694,079 tCO2eq, representing a 22.62% annual decline from 2023.

The company has committed to the Science Based Targets Initiative (SBTi), with targets due for submission for external validation by October 2025. In 2024, 34% of total energy consumption came from renewable sources. The waste diversion rate in 2024 was 54%. Taxonomy-aligned capital expenditures accounted for 13% of all capital expenditures in 2024. The company has started to carry out product lifecycle assessments. In 2024, 25% of total materials used were reused or recycled secondary materials. No carbon credits were purchased or planned for purchase in 2024. No environmental compliance violations were identified in fiscal year 2023. The net-zero target year for total emissions is 2045. Climate-related transition risks and opportunities were assessed based on TCFD classification, and climate-related transition risks were identified using a 1.5°C climate scenario. The company states no assets or business activities are jeopardized by climate-related risks in the short, medium, or long term. In 2024, 0% of water withdrawal was sourced from high water stress areas.

Respect for Cultures & Communities

The provided articles do not contain specific, quantifiable data points for any of the KPIs related to 'Respect for Cultures & Communities'. Multiple articles explicitly state the absence of data for metrics such as formal partnerships with indigenous communities, revenue reinvested in local development, cultural appropriation incidents, cultural impact assessment protocols, local employment ratios, grievance mechanism coverage, cultural preservation investments, or cultural sensitivity training completion.

Therefore, no KPIs can be scored based on the evidence provided.

Zero Waste & Sustainable Products

Sartorius diverted 54% of its total waste from disposal in 2024.

The estimated recyclable content of products sold, specifically for instruments, is 16% for 2024. In 2024, 18% of packaging was made from recyclable materials. For 2024, 25% of total materials used for product manufacture and services were reused or recycled secondary materials. The company achieved a 30.5% reduction in plastic use for Vivaflow® SU TFF Cassettes compared to the previous generation. Sartorius complies with the European WEEE Directive 2012/19/EU, requiring the take-back of old appliances for recycling. The company analyzes products for circularity principles, including service life, reuse, repairability, and recyclability. Sartorius has implemented ongoing operational waste management at some production sites, including recycling initiatives at Göttingen and Aubagne. Hazardous waste, such as organic solvents, is treated and largely recycled, with non-recyclable residues professionally disposed of. Instruments have an average expected durability of 9 years, with larger biopharmaceutical devices lasting up to 15 years. Sartorius emphasizes that its instruments are easy to repair and provides long-term spare parts. No waste disposal violations were reported in 2024. The company has a target for zero operational waste to landfill by 2030 and aims for zero-waste production by 2030 at its Quintix® Pro production facility. Sartorius’ Code of Conduct for Business Partners requires appropriate environmental protection management systems. The company provides information on recyclability for Vivaflow® SU and encourages proper disposal for products like Sartolab® RF|BT and Picus® 2.